Sarepta Therapeutics, Inc. (BMV:SRPT)

Market Cap	29.77B +15.1%
Revenue (ttm)	39.38B -2.2%
Net Income	1.17B
EPS	11.50
Shares Out	n/a
PE Ratio	25.39
Forward PE	6.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	294.00
Previous Close	294.00
Day's Range	294.00 - 294.00
52-Week Range	198.74 - 450.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 835
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: SRPT

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 21, 2026

Data Sources Report a data error